Package Leaflet: Information for the User
PREZISTA 400 mg film-coated tablets
darunavir
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Keep this leaflet, you may need to read it again.
Contents of the pack and other information
What is PREZISTA?
PREZISTA contains the active substance darunavir. PREZISTA is an antiretroviral medicine used in the treatment of infection by the Human Immunodeficiency Virus (HIV). It belongs to a group of medicines called protease inhibitors. PREZISTA reduces the amount of HIV in your body. This improves your immune system and reduces the risk of diseases associated with HIV infection.
What is it used for?
The 400 milligram PREZISTA tablet is used to treat adults and children (from 3 years of age and at least 40 kilograms in weight) infected with HIV and
PREZISTA must be taken with a low dose of cobicistat or ritonavir and other HIV medicines. Your doctor will explain which combination of medicines is best for you.
Do not take PREZISTA
Do not combine PREZISTA with any of the following medicines
If you are taking any of these medicines, consult your doctor to change to another medicine.
Do not combine PREZISTA with products that contain St. John's Wort (Hypericum perforatum)
perforatum).
Warnings and precautions
Consult your doctor, pharmacist, or nurse before you start taking PREZISTA.
PREZISTA does not cure HIV infection. While you are taking this medicine, you can still transmit HIV to others, although effective antiviral treatment reduces this risk. Consult your doctor about the precautions needed to avoid infecting others.
People taking PREZISTA may develop other infections or diseases associated with HIV infection. You must remain under regular medical care.
People taking PREZISTA may develop a skin rash. It is not common for the rash to be severe or life-threatening. Please consult your doctor if you develop a rash.
Patients taking PREZISTA and raltegravir (for HIV infection) may develop rashes (usually mild or moderate) more frequently than patients taking either of the two medicines separately.
Tell your doctor about your situation BEFORE and DURING treatment
Make sure you check the following points and tell your doctor if any apply to you.
It is believed that these symptoms are due to an improvement in the body's immune response, which allows it to fight off infections that were present without any apparent symptoms.
Elderly population
PREZISTA has only been used in a limited number of patients aged 65 years or older. If you belong to this age group, please talk to your doctor to see if you can use PREZISTA.
Children and adolescents
The 400 milligram PREZISTA tablet must not be used in children under 3 years of age or weighing less than 40 kilograms.
Taking PREZISTA with other medicines
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Some medicines must not be combinedwith PREZISTA. The list can be found in the section “Do not combine PREZISTA with any of the following medicines:”
In most cases, PREZISTA can be combined with HIV medicines that belong to other classes [e.g. NRTIs (nucleoside reverse transcriptase inhibitors), NNRTIs (non-nucleoside reverse transcriptase inhibitors), CCR5 antagonists, and FIs (fusion inhibitors)]. PREZISTA has not been tested with cobicistat or ritonavir with all HIV protease inhibitors and must not be used with other HIV protease inhibitors. In some cases, it may be necessary to change the dose of the other medicines. Therefore, if you are taking other anti-HIV medicines, always tell your doctor and follow their instructions carefully on which medicines can be combined.
The following products may reduce the effectiveness of PREZISTA. Tell your doctor if you are taking:
PREZISTA may also affect the effects of other medicines. Tell your doctor if you are taking:
In certain cases, it may be necessary to modify the dose of some medicines because when combined, the therapeutic or adverse effects of these or PREZISTA may be affected.
Tell your doctor if you are taking:
This is nota complete list of medicines. Tell your doctor about allthe medicines you are taking.
Taking PREZISTA with food and drinks
See section 3 “How to take PREZISTA.”
Pregnancy and breastfeeding
Tell your doctor immediately if you are pregnant, plan to become pregnant, or are breastfeeding. Pregnant or breastfeeding women must not take PREZISTA with ritonavir unless their doctor specifically instructs them to do so. Pregnant or breastfeeding women must not take PREZISTA with cobicistat.
It is recommended that women infected with HIV do not breastfeed their babies because there is a possibility that the babies may become infected with HIV through breast milk, as well as the unknown effects of the medicine on the babies.
Driving and using machines
Do not drive or use machines if you experience dizziness after taking PREZISTA.
PREZISTA tablets contain sunset yellow FCF (E110), which may cause allergic reactions.
Follow the administration instructions for this medication exactly as stated in this leaflet or as indicated by your doctor, pharmacist, or nurse. If you have any doubts, ask your doctor, pharmacist, or nurse.
Do not stop taking PREZISTA or cobicistat or ritonavir without consulting your doctor first, even if you feel better.
After starting treatment, do not change the dose or form of the dose or interrupt treatment without your doctor's instructions.
The 400-milligram PREZISTA tablets are used only to achieve the 800-milligram once-daily dosing regimen.
Dose for Adults Who Have Not Previously Taken Antiretroviral Medications (to be determined by your doctor)
The dose will be determined by your doctor)
The normal dose of PREZISTA is 800 milligrams (2 tablets of 400 milligrams of PREZISTA or 1 tablet containing 800 milligrams of PREZISTA) once a day.
You must take PREZISTA every day and always in combination with 150 milligrams of cobicistat or 100 milligrams of ritonavir and with food. PREZISTA does not work properly without cobicistat or ritonavir and food. Before taking PREZISTA and cobicistat or ritonavir, you must eat 30 minutes before. The type of food is not important.
Do not interrupt treatment with PREZISTA or cobicistat or ritonavir without consulting your doctor first, even if you feel better.
Instructions for Adults
Dose for Adults Who Have Previously Taken Antiretroviral Medications (to be determined by your doctor)
The dose is:
Or
Please talk to your doctor about which dose is correct for you.
Dose for Children 3 Years of Age and Older, Weighing More Than 40 Kilograms, Who Have Not Previously Taken Antiretroviral Medications (to be determined by your child's doctor)
Dose for Children 3 Years of Age and Older, Weighing More Than 40 Kilograms, Who Have Previously Taken Antiretroviral Medications (to be determined by your child's doctor)
The dose is:
Or
Please talk to your doctor about which dose is correct for you.
Instructions for Children 3 Years of Age and Older, Weighing More Than 40 Kilograms
Child-Resistant Cap Removal
The plastic bottle has a child-resistant safety cap and is opened as follows:
|
If You Take More PREZISTA Than You Should
Inform your doctor, pharmacist, or nurse immediately.
If You Forget to Take PREZISTA
If you realize within 12 hours, take the tablets immediately. Always take the dose with cobicistat or ritonavir and with food. If you realize after 12 hours, skip that dose and take the next one as usual. Do not take a double dose to make up for missed doses.
Do Not Stop Taking PREZISTA Without Talking to Your Doctor First
HIV medications can make you feel better. Even if you feel better, do not stop taking PREZISTA. Consult your doctor first.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
During HIV treatment, there may be an increase in weight and glucose and lipid levels in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of lipids in the blood, sometimes to HIV medications themselves. Your doctor will monitor these changes.
Like all medications, this medication can cause side effects, although not everyone will experience them.
Tell Your Doctor If You Develop Any of the Following Side Effects.
There have been reports of liver problems that can occasionally be severe. Your doctor will perform a blood test before you start treatment with PREZISTA. If you have a chronic infection caused by hepatitis B or C, your doctor will frequently check your blood tests, as there is a higher risk of developing liver problems. Talk to your doctor about the signs and symptoms of liver problems. These may include yellowing of the skin and the whites of the eyes, darkening (tea-colored) urine, pale stools, nausea, vomiting, loss of appetite, or pain, discomfort, or tenderness in the right side below your ribs.
Skin rash (more frequent when used in combination with raltegravir), itching. The skin rash is usually mild to moderate. A skin rash can also be a symptom of a rare and serious situation. Therefore, it is essential to talk to your doctor if you develop a rash. Your doctor will advise you on how to control the symptoms or if you should stop taking PREZISTA.
Other serious side effects were diabetes (frequent) and pancreatitis (infrequent).
Very common side effects (may affect more than 1 in 10 patients)
Common side effects (may affect up to 1 in 10 patients)
Uncommon side effects (may affect up to 1 in 100 patients)
Rare side effects (may affect up to 1 in 1,000 patients)
Some side effects are typical of HIV medications that belong to the same family as PREZISTA. These are:
Reporting Side Effects
If you experience any side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the box and on the bottle, after EXP. The expiration date is the last day of the month indicated.
PREZISTA does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any medication you no longer need. This will help protect the environment.
Composition of PREZISTA
Appearance of the Product and Package Contents
Film-coated tablet, oval, light orange in color, marked with TMC on one side and 400MG on the other side.
60 tablets in a plastic bottle.
PREZISTA is also available in 75-milligram, 150-milligram, 300-milligram, 600-milligram, and 800-milligram film-coated tablets and 100-milligram-per-milliliter oral suspension.
Marketing Authorization Holder
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium
Manufacturer
Janssen-Cilag SpA, Via C. Janssen, Borgo San Michele, 04100 Latina, Italy
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Janssen-Cilag NV Tel: +32 14 64 94 11 janssen@jacbe.jnj.com | Lithuania UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 lt@its.jnj.com |
Bulgaria "JOHNSON & JOHNSON" Ltd. Tel: +359 2 489 94 00 jjsafety@its.jnj.com | Luxembourg Janssen-Cilag NV Tel: +32 14 64 94 11 janssen@jacbe.jnj.com |
Czech Republic Janssen-Cilag s.r.o. Tel: +420 227 012 227 | Hungary Janssen-Cilag Kft. Tel: +36 1 884 2858 |
Denmark Janssen-Cilag A/S Tel: +45 4594 8282 jacdk@its.jnj.com | Malta AM MANGION LTD Tel: +356 2397 6000 |
Germany Janssen-Cilag GmbH Tel: +49 2137 955 955 jancil@its.jnj.com | Netherlands Janssen-Cilag B.V. Tel: +31 76 711 1111 janssen@jacnl.jnj.com |
Estonia UAB "JOHNSON & JOHNSON" Estonian branch Tel: +372 617 7410 ee@its.jnj.com | Norway Janssen-Cilag AS Tel: +47 24 12 65 00 jacno@its.jnj.com |
Greece Janssen-Cilag Φαρμακευτικ? Α.Ε.Β.Ε. Tel: +30 210 80 90 000 | Austria Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 |
Spain Janssen-Cilag, S.A. Tel: +34 91 722 81 00 infojaces@its.jnj.com | Poland Janssen-Cilag Polska Sp. z o.o. Tel: +48 22 237 60 00 |
France Janssen-Cilag Tel: 0 800 25 50 75 / +33 1 55 00 40 03 medisource@its.jnj.com | Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 |
Croatia Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 jjsafety@JNJCR.JNJ.com | Romania Johnson & Johnson Romania SRL Tel: +40 21 207 1800 |
Ireland Janssen Sciences Ireland UC Tel: +353 1 800 709 122 | Slovenia Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 Janssen_safety_slo@its.jnj.com |
Italy Janssen-Cilag SpA Tel: 800.688.777 / +39 02 2510 1 janssenita@its.jnj.com | Finland Janssen-Cilag Oy Tel: +358 207 531 300 jacfi@its.jnj.com |
Cyprus Βαρνάβας Χατζηπαναγής Λtd Tel: +357 22 207 700 | Sweden Janssen-Cilag AB Tel: +46 8 626 50 00 jacse@its.jnj.com |
Latvia UAB "JOHNSON & JOHNSON" Latvian branch Tel: +371 678 93561 lv@its.jnj.com | United Kingdom Janssen-Cilag Ltd. Tel: +44 1 494 567 444 |
Date of the Last Revision of this Leaflet:{MM/YYYY}.
Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.